These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 22991868)

  • 1. [Risk-sharing scheme in Israel--Kuvan as an allegory].
    Abadi-Korek I; Shemer J
    Harefuah; 2012 Jun; 151(6):362-3, 377, 376. PubMed ID: 22991868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria.
    Burnett JR
    IDrugs; 2007 Nov; 10(11):805-13. PubMed ID: 17968763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests.
    Hammerman A; Feder-Bubis P; Greenberg D
    Value Health; 2012; 15(5):737-42. PubMed ID: 22867784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sapropterin (Kuvan) for phenylketonuria.
    Med Lett Drugs Ther; 2008 Jun; 50(1287):43-4. PubMed ID: 18509266
    [No Abstract]   [Full Text] [Related]  

  • 6. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving patient selection and clinical benefit criteria for sapropterin dihydrochloride (Kuvan®) treatment of PKU patients.
    Gordon P; Thomas JA; Suter R; Jurecki E
    Mol Genet Metab; 2012 Apr; 105(4):672-6. PubMed ID: 22310224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel.
    Triki N; Ash N; Porath A; Birnbaum Y; Greenberg D; Hammerman A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):749-753. PubMed ID: 31825682
    [No Abstract]   [Full Text] [Related]  

  • 10. Sapropterin: a new therapeutic agent for phenylketonuria.
    Hegge KA; Horning KK; Peitz GJ; Hegge K
    Ann Pharmacother; 2009 Sep; 43(9):1466-73. PubMed ID: 19654333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.
    Neumann PJ; Chambers JD; Simon F; Meckley LM
    Health Aff (Millwood); 2011 Dec; 30(12):2329-37. PubMed ID: 22147861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk avoidance and missed opportunities in mental health reform: the case of Israel.
    Aviram U; Guy D; Sykes I
    Int J Law Psychiatry; 2007; 30(3):163-81. PubMed ID: 17467055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sapropterin dihydrochloride, 6-R-L-erythro-5,6,7,8-tetrahydrobiopterin, in the treatment of phenylketonuria.
    Michals-Matalon K
    Expert Opin Investig Drugs; 2008 Feb; 17(2):245-51. PubMed ID: 18230057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited options to manage specialty drug spending.
    Tu HT; Samuel DR
    Res Brief; 2012 Apr; (22):1-13. PubMed ID: 23155549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach.
    Antonanzas F; Juarez-Castello C; Rodriguez-Ibeas R
    Health Econ Policy Law; 2011 Jul; 6(3):391-403. PubMed ID: 21338542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The Dental and Pharmaceutical Benefits Agency misinterpret its mission].
    Carlsson U
    Lakartidningen; 2010 Jun 30-Jul 20; 107(26-28):1717; discussion 1718. PubMed ID: 20701155
    [No Abstract]   [Full Text] [Related]  

  • 17. Estimating the budget impact of new technologies added to the National List of Health Services in Israel: stakeholders' incentives for adopting a financial risk-sharing mechanism.
    Hammerman A; Greenberg D
    Health Policy; 2009 Jan; 89(1):78-83. PubMed ID: 18579253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?
    Edlin R; Hall P; Wallner K; McCabe C
    Value Health; 2014 Jun; 17(4):438-44. PubMed ID: 24969005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.